沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病的疗效观察

目的观察沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病(COPD)的临床疗效。方法 108例COPD患者,随机分为实验组和对照组,各54例。对照组予口服盐酸氨溴索片、茶碱缓释片等进行常规治疗,实验组在常规治疗的基础上同时给予沙美特罗替卡松粉吸入治疗。比较两组患者治疗前后的肺功能指标第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量的比值(FEV1/FVC)]、动脉血气分析指标动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)]、COPD评估测试(CAT)评分及不良反应发生情况。结果治疗后,对照组患者的FEV1为(1.68±0.13)L、FEV1/FVC为(52.44±6.81)%、PaO2为(64.40±7.89)mm Hg(1 mm Hg=0.133 kPa)、PaCO2为(51.60±6.50)mm Hg及CAT评分为(32.6±6.5)分,与本组治疗前的(1.61±0.13)L、(51.10±6.08)%、(62.00±7.15)mm Hg、(52.20±6.42)mm Hg及(33.1±6.7)分比较,差异均无统计学意义(P>0.05)。实验组患者的FEV1(1.94±0.11)L、FEV1/FVC (63.48±6.52)%、PaO2 (74.80±8.21)mm Hg均高于本组治疗前的(1.58±0.16)L、(50.90±5.96)%、(61.60±7.08)mm Hg, PaCO2 (40.80±6.35)mm Hg、CAT评分(21.8±5.8)分低于本组治疗前的(52.50±6.36)mm Hg、(32.4±6.5)分,差异均具有统计学意义(P<0.05)。实验组患者治疗后的FEV1、FEV1/FVC、PaO2水平均高于对照组, PaCO2、CAT评分低于对照组,差异均具有统计学意义(P<0.05)。两组患者均未出现明显的不良反应。结论采用沙美特罗替卡松粉吸入剂治疗COPD,能够显著改善患者的临床症状和肺功能。

Observation on efficacy of salmeterol xinafoate and fluticasone propionate powder for inhalation for the treatment of chronic obstructive pulmonary disease

Objective To observe the clinical efficacy of salmeterol xinafoate and fluticasone propionate powder for inhalation for the treatment of chronic obstructive pulmonary disease(COPD). Methods A total of 108 COPD patients were randomly divided into experimental group and control group, with 54 cases in each group. The control group received oral administration of ambroxol hydrochloride tablets and theophylline sustained-release tablets for conventional treatment, and the experimental group received salmeterol xinafoate and fluticasone propionate powder for inhalation on the basis of conventional treatment. The pulmonary function indexes forced expiratory volume in the 1 st second(FEV1) and FEV1/forced vital capacity(FEV1/FVC)], arterial blood gas analysis indexes arterial oxygen partial pressure(PaO2) and arterial carbon dioxide partial pressure(PaCO2)] and COPD assessment test(CAT) score before and after treatment and occurrence of adverse reactions were compared between the two groups. Results In the control group, FEV1, FEV1/FVC, PaO2, PaCO2, and CAT score after treatment were(1.68±0.13) L,(52.44±6.81)%,(64.40±7.89)mm Hg(1 mm Hg=0.133 kPa),(51.60±6.50) mm Hg and(32.6±6.5) points, which had no statistically significant difference compared with those before treatment(1.61±0.13) L,(51.10±6.08)%,(62.00±7.15) mm Hg,(52.20±6.42) mm Hg and(33.1±6.7) points(P>0.05). In the experimental group, FEV1, FEV1/FVC, PaO2 after treatment were(1.94±0.11) L,(63.48±6.52)%,(74.80±8.21) mm Hg, which were higher than those before treatment(1.58±0.16) L,(50.90±5.96)%,(61.60±7.08) mm Hg, and PaCO2, CAT score(40.80±6.35) mm Hg,(21.8±5.8) points were lower than those before treatment(52.50±6.36) mm Hg,(32.4±6.5) points. The difference was statistically significant(P<0.05). After treatment, FEV1, FEV1/FVC, PaO2 of the experimental group were higher than those of the control group, and PaCO2, CAT score were lower than those of the control group. The difference was statistically significant(P<0.05). There were no significant adverse reactions in both groups. Conclusion Salmeterol xinafoate and fluticasone propionate powder for inhalation can significantly improve the clinical symptoms and pulmonary function of COPD patients.